United States

ECRI's 2026 Patient Safety Report Puts $20 Billion Adverse Event Cost on Health System Agendas

SHERIDAN, WYOMING - April 14, 2026 - ECRI, the independent nonprofit that is the only U.S. organization holding dual designation as both an Evidence-based Practice Center and a Patient Safety Organization, has published its Top 10 Patient Safety Concerns for 2026, making the report available for immediate download to healthcare executives, safety officers, and clinical decision-makers. The release arrives as the organization's own cited data underscores the scale of the systemic challenge: one in four patients experiences an adverse event during inpatient care, and preventable harm costs U.S. healthcare organizations an estimated $20 billion each year. ECRI works with approximately two out of three U.S. healthcare providers, giving its annual safety priorities report broad operational reach across the sector.

Esaote Pushes Into Neurosurgery and U.S. Cardiology Channels While Rolling Out New Ultrasound Platforms

Image

SHERIDAN, WYOMING - April 14, 2026 - Esaote, one of the world's leading manufacturers of dedicated MRI and medical diagnostic imaging systems, has executed a series of product launches and a strategic distribution partnership over recent months. The company unveiled the MyLab™E85 GTS Edition featuring exclusive PAM technology at the 2026 European Association of Urology congress, presented new ultrasound and enterprise imaging capabilities at the European Congress of Radiology in March, and entered the neurosurgery segment with the I-Genius intraoperative MRI system at the 25th EANS Annual Congress. In November 2025, Esaote and Schiller Americas formalized a partnership to expand the cardiology imaging sales channel in the United States. Taken together, these moves represent a coordinated push across specialties, geographies, and imaging modalities.

Beautiful.ai Rolls Out Iterative AI Presentation Workflow to Eliminate Deck Rework for Business Teams

Image

SHERIDAN, WYOMING - April 14, 2026 - Beautiful.ai has launched "Create with AI," a restructured presentation workflow that moves away from one-shot AI generation toward a guided, multi-stage process. The platform targets business teams in sales, marketing, consulting, and enterprise functions where presentation quality, brand consistency, and collaborative editing carry operational weight. The new workflow positions Beautiful.ai against generic AI slide generators by embedding iteration directly into the creation sequence, rather than leaving users to manually correct first-draft output. The company describes the change as the removal of what it calls the "first output lottery" problem common to AI deck tools.

InspireMD's CGuard Prime Claims Lowest Adjudicated Adverse Event Rates in Pivotal Carotid Stenting Evidence

SHERIDAN, WYOMING - April 14, 2026 - InspireMD, a medical technology company specializing in vascular disease treatment and embolic protection, is positioning its CGuard Prime carotid stent system as a clinical performance benchmark in carotid artery stenting, citing independently adjudicated trial data showing a 0.95% composite major adverse event rate at 30 days and 1.93% at one year-figures the company characterizes as the lowest of any pivotal carotid stenting study to date. The device's dual-layer MicroNet™ mesh architecture directly targets late embolization through stent struts, a failure mode associated with approximately two-thirds of major adverse events following carotid artery stenting procedures according to published vascular surgery research. CGuard Prime carries FDA clearance for use in high-surgical-risk patients requiring carotid revascularization and is marketed across U.S. and international markets.

U.S. Staffing Employment Up 5.3% Year-Over-Year as ASA March Index Holds at 87

SHERIDAN, WYOMING - April 14, 2026 - The American Staffing Association reported that its monthly Staffing Index rose marginally by 0.1% week-to-week for the period of March 9-15, 2026, settling at a rounded value of 87. Year-over-year, staffing employment was 5.3% higher compared to the same period in 2025, indicating that underlying demand for temporary and contract workers has maintained an upward trajectory even as near-term weekly momentum remains subdued. Staffing companies surveyed during the reporting period cited no single factor as a primary barrier to growth, a finding that complicates sector-specific diagnosis but also indicates that demand softness is broadly distributed rather than concentrated in one industry vertical. ASA published the data on March 24, 2026, as part of its ongoing monthly index series.

Globee Awards Names 2026 Excellence Winners as Final Entry Deadlines Approach Across Multiple Programs

SHERIDAN, WYOMING - April 14, 2026 - The Globee® Awards has announced winners for its 13th Annual 2026 Awards for Excellence, marking the latest cycle completion in a portfolio of ten active recognition programs targeting business performance, leadership, innovation, and organizational achievement worldwide. The announcement comes as multiple other Globee programs enter their final submission windows, with the Achievement and Artificial Intelligence categories reaching last-chance deadlines on April 22 and April 23 respectively. San Francisco-based Globee® operates award programs spanning categories from cybersecurity and AI to business leadership and emerging technology, drawing entries from organizations across global markets.

Healogics Scales U.S. Advanced Wound Care Network to 600-Plus Centers, Backed by Five-Million-Wound Clinical Database

SHERIDAN, WYOMING - April 14, 2026 - Healogics, LLC, headquartered in Jacksonville, Florida, operates more than 600 hospital-based Wound Care Centers® across the United States, making it the country's largest provider of advanced wound care and hyperbaric oxygen therapy. The company has treated patients with chronic wounds for 30 years, currently serving over 300,000 patients annually and reporting nearly four million wounds healed across its managed network. With an estimated seven million Americans living with chronic, non-healing wounds, Healogics positions itself as a clinical and operational resource for hospital systems, payers, and providers seeking to reduce the long-term burden of complex wound management.

Philatron Positions US-Made Wire and Cable Across Fourteen Industrial End Markets

SHERIDAN, WYOMING - April 14, 2026 - Philatron Wire and Cable, headquartered in Santa Fe Springs, California, operates as a full-service US manufacturer of bulk wire, cable supply, and molded electrical cable assemblies, with a defined specialization in extra-large flexible cables and coiled cord solutions. The company serves fourteen end markets-including airport ground support, electric vehicles, military, mining, oil and gas, and utility power-and positions its domestic manufacturing footprint as a core differentiator in a sector where supply chain origin is an active procurement consideration. All products are manufactured in the United States under a 100% Made in USA designation, and the company holds industry certifications that support compliance-sensitive purchasing categories.

NS Pharma Advances Brogidirsen to 4.5-Year Data Milestone as DMD Pipeline and EGPA Phase 2 Expand

SHERIDAN, WYOMING - April 14, 2026 - NS Pharma, Inc., a U.S.-based biopharmaceutical subsidiary of Japan's Nippon Shinyaku Co., Ltd., presented 4.5-year clinical trial data for brogidirsen (NS-089/NCNP-02) at the 2026 MDA Clinical & Scientific Conference on March 6, 2026, representing the most extensive longitudinal dataset disclosed to date for this Duchenne muscular dystrophy exon-skipping candidate. The presentation followed a 3.5-year data readout at the 2025 World Muscle Society Congress in October 2025, reflecting a deliberate, incremental evidence-building strategy for the compound. Concurrently, the company's JAK1 inhibitor NS-229 has entered a global Phase 2 trial for eosinophilic granulomatosis with polyangiitis (EGPA), extending NS Pharma's clinical footprint beyond neurology into rare inflammatory disease.

Sanford Heisler Sharp McKnight Builds Record-Setting Track in Employment and Whistleblower Litigation

SHERIDAN, WYOMING - April 14, 2026 - Sanford Heisler Sharp McKnight, a U.S. employment law and civil rights firm operating from six offices nationwide, has assembled one of the most quantified litigation records in its sector, having recovered over $4 billion for whistleblowers and the federal government alongside nearly half a billion dollars in class action recoveries spanning employment discrimination, wage and hour claims, and ERISA violations. The firm holds the distinction of achieving the largest jury verdict in U.S. history in an employment discrimination case - a $253 million award against a major pharmaceutical company - and the largest known Title IX jury verdict in U.S. history. Its client base extends across Fortune 500 employees, C-suite executives, attorneys, university faculty, and government contractors.